The critical, clinical role of interferon-beta in regulating cancer stem cell properties in triple-negative breast cancer

DNA and Cell Biology

Volumn 37, Issue 6, 2018, Pages 513-516

  Doherty, Mary R ^a   Jackson, Mark W ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cancer stem cells; interferon beta; triple negative breast cancer

Indexed keywords

BETA INTERFERON; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER STEM CELL; HUMAN; MESENCHYMAL STEM CELL; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN TARGETING; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; DRUG EFFECT; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON-BETA; NEOPLASTIC STEM CELLS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 85048235565     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2018.4247     Document Type: Article

References (17)

1. Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, et al. (2012). Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 18, 1224-1231.
2. Brockwell NK, Owen KL, Zanker D, Spurling A, Rautela J, Duivenvoorden HM, et al. (2017). Neoadjuvant interferons: Critical for effective PD-1-based immunotherapy in TNBC. Cancer Immunol Res 5, 871-884.
3. Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fugua SA, et al. (2015). Comprehensive genomic analysis identifies novel subtypes and targets of triplenegative breast cancer. Clin Cancer Res 21, 1688-1698.
4. Cheon H, Holvey-Bates EG, Schoggins JW, Forster S, Hertzog P, Imanaka N, et al. (2013). IFNb-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J 32, 2751-2763.
5. Doherty MR, Cheon H, Junk DJ, Vinayak S, Varadan V, Telli ML, et al. (2017). Interferon-beta represses cancer stem cell properties in triple negative breast cancer. Proc Natl Acad Sci USA 114, 13792-13797.
6. Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, et al. (2009). IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 458, 904-908.
7. Garcin G, Paul F, Staufenbiel M, Bordat Y, Heyden JVD, Wilmes, S, et al. (2014). High efficiency cell-specific targeting of cytokine activity. Nat Commun 5, 3016.1-9.
8. Hu Y, Liu C, Muyldermans S. (2017). Nanobody-based delivery systems for diagnosis and targeted tumor therapy. Front Immunol 8, 1-17.
9. Ling X, Marini F, Konopleva M, Schober W, Shi Y, Burks J, et al. (2010). Mesenchymal stem cells overexpressing interferon-b inhibit breast cancer growth and metastases through stat3 signaling in a syngeneic tumor model. Cancer Microenviron 3, 83-95.
10. Parker BS, Rautela J, Hertzog PJ. (2016). Antitumour actions of interferons: Implications for cancer therapy. Nat Rev Cancer 16, 131-144.
11. Porritt RA, Hertzog PJ. (2015). Dynamic control of type I IFN signaling by an integrated network of negative regulators. Trends Immunol 36, 150-160.
12. Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, et al. (2014). Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 20, 1301-1309.
13. Slaney CY, Moller A, Hertzog PJ, Parker BS. (2013). The role of type I interferons in immunoregulation of breast cancer metastasis to the bone. Oncoimmunology 2, 1-3.
14. Steeland S, Vandenbrouke RE, Libert C. (2016). Nanobodies as therapeutics: Big opportunities for small antibodies. Drug Discov Today 21, 1076-1113.
15. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N, et al. (2008). An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci USA 105, 18490-18495.
16. Yang X, Zhang X, Fu ML, Weichselbaum RR, Gajewski TF, Guo Y, et al. (2014). Targeting the tumormicroenvironmentwith IFNb bridges innate and adaptive immune responses. Cell 25, 37-48.
17. Yu LY, Tang J, Zhang CM, Zeng WJ, Yan H, Li, MP, et al. (2017). New immunotherapy strategies in breast cancer. Int J Environ Res Public Health 14, 1-18.